2013 American Transplant Congress
Inhibition of IL-6/IL-6R Interactions by Anti-IL-6R Monoclonal Antibody Suppresses Donor Specific Antibody Responses in a Mouse Model of HLA Sensitization
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Purpose Tocilizumab®, a monoclonal antibody to the IL-6R was recently approved by the FDA for treatment of rheumatoid arthritis. Although anti-IL-6R antibodies can reduce autoantibody…2013 American Transplant Congress
T-Cell Depletion by Anti-CD3ε Is Associated with Dyshomeostasis in the Immature B-Cell Pool
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Purpose T-cell depletion by immunosuppressive antibodies has been increasingly used in treatment and prevention of allograft rejection. However, the impact of T-cell depletion on B-cell…2013 American Transplant Congress
Standardization through an Integrated Research Support Service for Discovery and Translational Transplant Research
Surgery, Emory University, Atlanta, GA
Innovative transplant research depends on the standardized acquisition and processing of well characterized biological samples. In order to optimize the usage of our Integrated Research…2013 American Transplant Congress
History of Chronic Opioid Usage and Early Post Transplant Outcomes
Introduction: Chronic opioids usage (COU) is highly prevalent among ESRD patients and can be associated with adverse clinic outcomes. We studied the relationship between a…2013 American Transplant Congress
Significant Impact of Prolonged Brain Death Duration on Patient Survival after Kidney Transplantation
Introduction: In renal transplantation, graft survival using organs from deceased donors is inferior to results after living donation. Little however is known about the effect…2013 American Transplant Congress
Follicular Helper T Cell Modulation by Costimulation Blockade Prevents Antibody-Mediated Rejection in Nonhuman Primate Renal Transplantation
Surgery, Emory University, Atlanta, GA; Pathology, Emory University, Atlanta, GA
[Background] De novo donor-specific antibody (DSA) after organ transplantation promotes antibody-mediated rejection (AMR) and causes late graft loss. Nearly a third of transplant recipients develop…2013 American Transplant Congress
Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results from the Long-Term Extension (LTE) of the Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) Study
Background: The BENEFIT trial compared a more (MI) or less intensive (LI) regimen of belatacept (bela) to cyclosporine (CsA) in patients receiving a living or…2013 American Transplant Congress
Likelihood of Improving or Maintaining Renal Function over Five Years with Belatacept or CsA: Insights from the BENEFIT Long-Term Extension Study
Introduction: In results reported from BENEFIT, the renal function benefit observed in belatacept (bela)-treated pts in the early post-transplant period was maintained over time with…2013 American Transplant Congress
Associations of Estimated GFR and Urinary Protein Excretion with Mortality and Graft Failure Following Kidney Transplantation
Chronic kidney disease (CKD) stage, defined by estimated glomerular filtration rate (eGFR) and urinary protein excretion, predicts outcomes in native CKD, but the associations of…2013 American Transplant Congress
Cohort Study of Solid Organ Transplant Recipients Who Develop Malignancy: Risk of Subsequent Malignancy on mTOR vs. Non-mTOR Regimens, A
Organ transplant recipients (OTR) have a reported 3-4 fold increased incidence of malignancy as compared to the general population. Malignancy has been associated with the…
- « Previous Page
- 1
- …
- 135
- 136
- 137
- 138
- 139
- …
- 178
- Next Page »